Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $744.13M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.63M
Average 0.52M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Immunome, Inc. NASDAQ:IMNM | $2.22B | $18.77 | Not rated | -9.1 | -3.81% |
Aktis Oncology, Inc. NASDAQ:AKTS | $893.27M | $16.62 | Not rated | -28.7 | — |
Oculis Holding AG NASDAQ:OCS | $471.63M | $7.64 | Not rated | -5.5 | -61.07% |
Ocugen, Inc. NASDAQ:OCGN | $280.88M | $0.83 | Not rated | -5.6 | -34.20% |
Bicycle Therapeutics plc NASDAQ:BCYC | $236.22M | $3.37 | Not rated | -1.3 | -50.54% |
Whitehawk Therapeutics Inc NASDAQ:WHWK | $180.57M | $3.06 | Not rated | -2.6 | +43.93% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +33.12% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $100.54M | $0.41 | Not rated | -2.1 | -81.12% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $69.86M | $3.39 | Not rated | -1.3 | -74.94% |
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | $25.66M | $0.31 | Not rated | -4.2 | -78.58% |
Continue the stock analysis
Jump to another research area for this company.